Association between tumor tissue TIMP-1 levels and objective response to first-line chemotherapy in metastatic breast cancer

Marie Klintman; Sidse Ørnbjerg Würtz; Ib Jarle Christensen; Pernille Bræmer  Hertel; Mårten Fernö; Martin Malmberg; Henning Mouridsen; Frederik Cold; Anne-Sofie Schrohl; John A. Foekens; Per Malmström; Nils Brünner

doi:10.1007/s10549-009-0483-1

Association between tumor tissue TIMP-1 levels and objective response to first-line chemotherapy in metastatic breast cancer

Marie Klintman, Sidse Ørnbjerg Würtz, Ib Jarle Christensen, Pernille Bræmer Hertel, Mårten Fernö, Martin Malmberg, Henning Mouridsen, Frederik Cold, Anne-Sofie Schrohl, John A. Foekens, Per Malmström, Nils Brünner

13 Citations (Scopus)

Abstract

In a previous study from our laboratory, high tumor levels of tissue inhibitor of metalloproteinases-1 (TIMP-1) have been associated with an adverse response to chemotherapy in metastatic breast cancer suggesting that TIMP-1, which is known to inhibit apoptosis, may be a new predictive marker in this disease. The purpose of this study was to investigate the association between TIMP-1 and objective response to chemotherapy in an independent patient population consisting of patients with metastatic breast cancer from Sweden and Denmark. TIMP-1 was measured using ELISA in 162 primary tumor extracts from patients who later developed metastatic breast cancer and these levels were related to the objective response to first-line chemotherapy. Increasing levels of TIMP-1 were associated with a decreasing probability of response to treatment, reaching borderline significance (OR = 1.59, 95% CI: 0.97-2.62, P = 0.07). This OR is very similar to the result from our previous study. Increasing levels of TIMP-1 were also associated with a shorter disease-free survival and overall survival, however, not statistically significant. The results from the present study support previous data that TIMP-1 is associated with objective response to chemotherapy for metastatic breast cancer.

Original language	English
Journal	Breast Cancer Research and Treatment
Volume	121
Issue number	2
Pages (from-to)	365-371
Number of pages	7
ISSN	0167-6806
DOIs	https://doi.org/10.1007/s10549-009-0483-1
Publication status	Published - Jun 2010

UN SDGs

This output contributes to the following UN Sustainable Development Goals (SDGs)

Access to Document

10.1007/s10549-009-0483-1

Cite this

Klintman, M., Würtz, S. Ø., Christensen, I. J., Hertel, P. B., Fernö, M., Malmberg, M., Mouridsen, H., Cold, F., Schrohl, A-S., Foekens, J. A., Malmström, P., & Brünner, N. (2010). Association between tumor tissue TIMP-1 levels and objective response to first-line chemotherapy in metastatic breast cancer. Breast Cancer Research and Treatment, 121(2), 365-371. https://doi.org/10.1007/s10549-009-0483-1

Klintman, M, Würtz, SØ, Christensen, IJ, Hertel, PB, Fernö, M, Malmberg, M, Mouridsen, H, Cold, F, Schrohl, A-S, Foekens, JA, Malmström, P & Brünner, N 2010, 'Association between tumor tissue TIMP-1 levels and objective response to first-line chemotherapy in metastatic breast cancer', Breast Cancer Research and Treatment, vol. 121, no. 2, pp. 365-371. https://doi.org/10.1007/s10549-009-0483-1

@article{602db530bd5d11debda0000ea68e967b,

title = "Association between tumor tissue TIMP-1 levels and objective response to first-line chemotherapy in metastatic breast cancer",

abstract = "In a previous study from our laboratory, high tumor levels of tissue inhibitor of metalloproteinases-1 (TIMP-1) have been associated with an adverse response to chemotherapy in metastatic breast cancer suggesting that TIMP-1, which is known to inhibit apoptosis, may be a new predictive marker in this disease. The purpose of this study was to investigate the association between TIMP-1 and objective response to chemotherapy in an independent patient population consisting of patients with metastatic breast cancer from Sweden and Denmark. TIMP-1 was measured using ELISA in 162 primary tumor extracts from patients who later developed metastatic breast cancer and these levels were related to the objective response to first-line chemotherapy. Increasing levels of TIMP-1 were associated with a decreasing probability of response to treatment, reaching borderline significance (OR = 1.59, 95% CI: 0.97-2.62, P = 0.07). This OR is very similar to the result from our previous study. Increasing levels of TIMP-1 were also associated with a shorter disease-free survival and overall survival, however, not statistically significant. The results from the present study support previous data that TIMP-1 is associated with objective response to chemotherapy for metastatic breast cancer.",

author = "Marie Klintman and W{\"u}rtz, {Sidse {\O}rnbjerg} and Christensen, {Ib Jarle} and Hertel, {Pernille Br{\ae}mer} and M{\aa}rten Fern{\"o} and Martin Malmberg and Henning Mouridsen and Frederik Cold and Anne-Sofie Schrohl and Foekens, {John A.} and Per Malmstr{\"o}m and Nils Br{\"u}nner",

year = "2010",

month = jun,

doi = "10.1007/s10549-009-0483-1",

language = "English",

volume = "121",

pages = "365--371",

journal = "Breast Cancer Research and Treatment",

issn = "0167-6806",

publisher = "Springer",

number = "2",

}

TY - JOUR

T1 - Association between tumor tissue TIMP-1 levels and objective response to first-line chemotherapy in metastatic breast cancer

AU - Klintman, Marie

AU - Würtz, Sidse Ørnbjerg

AU - Christensen, Ib Jarle

AU - Hertel, Pernille Bræmer

AU - Fernö, Mårten

AU - Malmberg, Martin

AU - Mouridsen, Henning

AU - Cold, Frederik

AU - Schrohl, Anne-Sofie

AU - Foekens, John A.

AU - Malmström, Per

AU - Brünner, Nils

PY - 2010/6

Y1 - 2010/6

N2 - In a previous study from our laboratory, high tumor levels of tissue inhibitor of metalloproteinases-1 (TIMP-1) have been associated with an adverse response to chemotherapy in metastatic breast cancer suggesting that TIMP-1, which is known to inhibit apoptosis, may be a new predictive marker in this disease. The purpose of this study was to investigate the association between TIMP-1 and objective response to chemotherapy in an independent patient population consisting of patients with metastatic breast cancer from Sweden and Denmark. TIMP-1 was measured using ELISA in 162 primary tumor extracts from patients who later developed metastatic breast cancer and these levels were related to the objective response to first-line chemotherapy. Increasing levels of TIMP-1 were associated with a decreasing probability of response to treatment, reaching borderline significance (OR = 1.59, 95% CI: 0.97-2.62, P = 0.07). This OR is very similar to the result from our previous study. Increasing levels of TIMP-1 were also associated with a shorter disease-free survival and overall survival, however, not statistically significant. The results from the present study support previous data that TIMP-1 is associated with objective response to chemotherapy for metastatic breast cancer.

AB - In a previous study from our laboratory, high tumor levels of tissue inhibitor of metalloproteinases-1 (TIMP-1) have been associated with an adverse response to chemotherapy in metastatic breast cancer suggesting that TIMP-1, which is known to inhibit apoptosis, may be a new predictive marker in this disease. The purpose of this study was to investigate the association between TIMP-1 and objective response to chemotherapy in an independent patient population consisting of patients with metastatic breast cancer from Sweden and Denmark. TIMP-1 was measured using ELISA in 162 primary tumor extracts from patients who later developed metastatic breast cancer and these levels were related to the objective response to first-line chemotherapy. Increasing levels of TIMP-1 were associated with a decreasing probability of response to treatment, reaching borderline significance (OR = 1.59, 95% CI: 0.97-2.62, P = 0.07). This OR is very similar to the result from our previous study. Increasing levels of TIMP-1 were also associated with a shorter disease-free survival and overall survival, however, not statistically significant. The results from the present study support previous data that TIMP-1 is associated with objective response to chemotherapy for metastatic breast cancer.

U2 - 10.1007/s10549-009-0483-1

DO - 10.1007/s10549-009-0483-1

M3 - Journal article

C2 - 19653096

SN - 0167-6806

VL - 121

SP - 365

EP - 371

JO - Breast Cancer Research and Treatment

JF - Breast Cancer Research and Treatment

IS - 2

ER -

Association between tumor tissue TIMP-1 levels and objective response to first-line chemotherapy in metastatic breast cancer

Abstract

UN SDGs

Access to Document

Fingerprint

Cite this